a.) Amendment to the Claims

1. (Currently Amended) A piperidine derivative represented by formula (I):

$$O_2N$$

$$\downarrow$$

$$\downarrow$$

$$X (CH_2)_mR^3$$

wherein

m represents an integer of 0 to 5;

R¹ and R² independently represent a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group;

R³ represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group; and

X represents a bond or CO;

or a pharmaceutically acceptable salt thereof,

wherein the heterocyclic groups in R¹, R² and R³ independently represent benzopyranyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, furyl, imidazolyl, imidazolyl, indolyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyrazolinyl, pyrazolyl, thiadiazolyl, thiadiazolyl or thienyl.

- 2. (Original) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein R¹ is a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group, and R² is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group.
- 3. (Original) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 1 and X is a bond.
- 4. (Original) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 2, wherein m is 1 and X is a bond.
- 5. (Original) A pharmaceutical composition which comprises as an active ingredient the piperidine derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, and a pharmaceutically acceptable diluent or carrier.
- 6. (Currently Amended) A method of treating a patient with colon and pancreatic colon or pancreatic cancer, which comprises administrating to said patient a pharmacologically effective amount of the piperidine derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.
- 7. (Previously Presented) The method of treating a patient according to claim 9, wherein the tumor is pancreatic cancer.

- 8. (Previously Presented) The method of treating a patient according to claim 9, wherein the tumor is colon cancer.
- 9. (Currently Amended) The method of treating a patient according to claim 6, wherein the colon and pancreatic colon or pancreatic cancer is a tumor.
- 10. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 0.
- 11. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 1.
- 12. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 2.
- 13. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 3.
- 14. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 4.
- 15. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 5.

- 16. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 10, wherein X is a bond.
- 17. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 12, wherein X is a bond.
- 18. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 13, wherein X is a bond.
- 19. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 14, wherein X is a bond.
- 20. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 15, wherein X is a bond.
- 21. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 10, wherein X is CO.
- 22. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 11, wherein X is CO.
- 23. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 12, wherein X is CO.

- 24. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 13, wherein X is CO.
- 25. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 14, wherein X is CO.
- 26. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 15 wherein X is CO.